Total Payments
$15,604
2024 Payments
$1,215
Companies
20
Transactions
312
Medicare Patients
1,472
Medicare Billing
$568,983
Payment Breakdown by Category
Food & Beverage$15,436 (98.9%)
Education$167.82 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,436 | 305 | 98.9% |
| Education | $167.82 | 7 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $5,989 | 94 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $2,436 | 47 | $0 (2020) |
| Allergan, Inc. | $1,512 | 22 | $0 (2020) |
| Alkermes, Inc. | $1,085 | 23 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,020 | 31 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $948.43 | 16 | $0 (2020) |
| Lundbeck LLC | $757.90 | 46 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $510.53 | 8 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $364.69 | 3 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $332.03 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,215 | 41 | Otsuka America Pharmaceutical, Inc. ($582.65) |
| 2023 | $801.84 | 18 | Otsuka America Pharmaceutical, Inc. ($442.84) |
| 2022 | $797.76 | 14 | Otsuka America Pharmaceutical, Inc. ($287.96) |
| 2021 | $735.40 | 19 | Alkermes, Inc. ($299.80) |
| 2020 | $937.56 | 28 | Otsuka America Pharmaceutical, Inc. ($383.58) |
| 2019 | $3,558 | 75 | Otsuka America Pharmaceutical, Inc. ($1,423) |
| 2018 | $3,532 | 57 | Sunovion Pharmaceuticals Inc. ($1,087) |
| 2017 | $4,026 | 60 | Otsuka America Pharmaceutical, Inc. ($1,713) |
All Payment Transactions
312 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $27.66 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Food and Beverage | In-kind items and services | $119.07 | General |
| Category: CNS | ||||||
| 11/12/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $27.46 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $27.81 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $1.99 | General |
| Category: PSYCHIATRY | ||||||
| 10/22/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 10/07/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Education | In-kind items and services | $27.27 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/01/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $28.48 | General |
| Category: PSYCHIATRY | ||||||
| 09/24/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: PSYCHIATRY | ||||||
| 09/03/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $21.93 | General |
| Category: PSYCHIATRY | ||||||
| 09/03/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $0.98 | General |
| Category: PSYCHIATRY | ||||||
| 08/13/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $32.23 | General |
| Category: PSYCHIATRY | ||||||
| 08/12/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $119.26 | General |
| Category: PSYCHIATRY | ||||||
| 08/06/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $11.66 | General |
| Category: PSYCHIATRY | ||||||
| 07/30/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: PSYCHIATRY | ||||||
| 07/30/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $3.06 | General |
| Category: PSYCHIATRY | ||||||
| 07/16/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $25.81 | General |
| Category: PSYCHIATRY | ||||||
| 07/16/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $2.40 | General |
| Category: PSYCHIATRY | ||||||
| 06/25/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $29.31 | General |
| Category: PSYCHIATRY | ||||||
| 06/25/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $2.72 | General |
| Category: PSYCHIATRY | ||||||
| 06/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: PSYCHIATRY | ||||||
| 06/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: PSYCHIATRY | ||||||
| 05/14/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $26.53 | General |
| Category: PSYCHIATRY | ||||||
| 05/14/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $1.71 | General |
| Category: PSYCHIATRY | ||||||
| 05/07/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 419 | 2,327 | $495,582 | $158,839 |
| 2022 | 5 | 312 | 2,201 | $453,473 | $155,317 |
| 2021 | 6 | 347 | 2,049 | $342,783 | $150,195 |
| 2020 | 6 | 394 | 1,816 | $242,735 | $104,632 |
Total Patients
1,472
Total Services
8,393
Medicare Billing
$568,983
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 126 | 679 | $203,700 | $52,586 | 25.8% |
| 90832 | Psychotherapy, 30 minutes | Office | 2023 | 33 | 785 | $88,767 | $49,706 | 56.0% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 120 | 619 | $125,657 | $36,753 | 29.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 43 | 95 | $28,500 | $5,001 | 17.5% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2023 | 34 | 35 | $13,652 | $4,720 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 21 | 35 | $13,720 | $3,806 | 27.7% |
| 90847 | Family psychotherapy with patient, 50 minutes | Office | 2023 | 19 | 46 | $13,294 | $3,754 | 28.2% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 23 | 33 | $8,292 | $2,513 | 30.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 127 | 754 | $226,200 | $60,434 | 26.7% |
| 90832 | Psychotherapy, 30 minutes | Office | 2022 | 29 | 804 | $91,353 | $53,182 | 58.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 116 | 586 | $118,958 | $35,638 | 30.0% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2022 | 23 | 23 | $7,136 | $3,161 | 44.3% |
| 90847 | Family psychotherapy with patient, 50 minutes | Office | 2022 | 17 | 34 | $9,826 | $2,903 | 29.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 120 | 757 | $144,093 | $61,504 | 42.7% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 123 | 710 | $116,640 | $43,544 | 37.3% |
| 90832 | Psychotherapy, 30 minutes | Office | 2021 | 19 | 445 | $50,812 | $28,941 | 57.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 40 | 69 | $15,912 | $8,488 | 53.3% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2021 | 27 | 27 | $7,786 | $3,940 | 50.6% |
| 90847 | Family psychotherapy including patient, 50 minutes | Office | 2021 | 18 | 41 | $7,540 | $3,777 | 50.1% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 125 | 651 | $99,009 | $39,462 | 39.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 112 | 366 | $55,972 | $25,168 | 45.0% |
| 90832 | Psychotherapy, 30 minutes | Office | 2020 | 17 | 363 | $40,951 | $21,078 | 51.5% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 111 | 392 | $39,705 | $14,388 | 36.2% |
| 90847 | Family psychotherapy including patient, 50 minutes | Office | 2020 | 16 | 31 | $4,650 | $2,938 | 63.2% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2020 | 13 | 13 | $2,449 | $1,598 | 65.3% |
About Dr. Hamid Moussavian, MD
Dr. Hamid Moussavian, MD is a Psychiatry healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1861541013.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hamid Moussavian, MD has received a total of $15,604 in payments from pharmaceutical and medical device companies, with $1,215 received in 2024. These payments were reported across 312 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($15,436).
As a Medicare-enrolled provider, Moussavian has provided services to 1,472 Medicare beneficiaries, totaling 8,393 services with total Medicare billing of $568,983. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location New York, NY
- Active Since 01/09/2007
- Last Updated 06/06/2018
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1861541013
Products in Payments
- ABILIFY MAINTENA (Drug) $3,231
- REXULTI (Drug) $3,105
- LATUDA (Drug) $2,436
- VRAYLAR (Drug) $1,509
- AUSTEDO (Drug) $832.34
- NUEDEXTA (Drug) $510.53
- LYBALVI (Drug) $493.38
- ARISTADA (Drug) $425.67
- SPRAVATO (Drug) $417.41
- INVEGA SUSTENNA (Drug) $355.01
- INGREZZA (Drug) $332.03
- ABILIFY MYCITE (Drug) $207.12
- ABILIFY ASIMTUFII (Drug) $185.57
- Jornay PM 20mg capsules (Bottle of 100) (Drug) $127.00
- BELSOMRA (Drug) $125.00
- NUPLAZID (Drug) $125.00
- VIVITROL (Drug) $125.00
- NAMENDA XR (Drug) $95.37
- HETLIOZ (Drug) $65.92
- UZEDY (Drug) $63.08
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in New York
Dr. Manish Zinzuvadia, M.d, M.D
Psychiatry — Payments: $1.3M
Psychiatry $1.3M
Dr. Jianping Chen, M.d, M.D
Psychiatry — Payments: $1.1M
Psychiatry $1.1M
Dr. Ulla Laakso, Md, MD
Psychiatry — Payments: $957,236
Psychiatry $957,236
Dr. Kerry Sulkowicz, M.d, M.D
Psychiatry — Payments: $476,134
Psychiatry $476,134
Dr. Ralph Aquila, M.d, M.D
Psychiatry — Payments: $327,213
Psychiatry $327,213
Dr. Paul Eder, M.d, M.D
Psychiatry — Payments: $278,989
Psychiatry $278,989